Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

Maintenance treatment regimens for patients with schizophrenia are often suboptimal. Partial adherence and outright noncompliance are associated with symptom recurrence and increased likelihood of rehospitalization. Long-acting conventional neuroleptics have limited efficacy and are associated with treatment-limiting adverse events, while oral atypical antipsychotics have not improved adherence substantially. A long-acting formulation of risperidone, an atypical antipsychotic with proven efficacy, has been developed. Introduction of long-acting injectable treatment may be appropriate during inpatient hospitalization, when consequences of relapse are most evident. To support this intervention, a subanalysis of patients who were inpatients at study initiation was conducted from a 12-week, double-blind, placebo-controlled long-acting risperidone study (N = 214). Long-acting risperidone was associated with a significant reduction in total Positive and Negative Syndrome Scale (PANSS) score (mean change +/- standard error [S.E.] at endpoint: long-acting risperidone, -9.27 +/- 1.44, n = 133; placebo, 0.72 +/- 2.59, n = 41; P < 0.001), and a significantly higher rate of treatment response, defined as > or = 20% reduction in total PANSS score (50% vs. 27%, P < 0.05). Significantly more long-acting risperidone patients had endpoint Clinical Global Impressions (CGI) assessments of not ill, very mild or mild (32% vs. 5%; P < 0.01). Long-acting risperidone was well tolerated. Long-acting risperidone initiated during inpatient treatment may be an important strategy in improving long-term outcomes among patients with schizophrenia.

Full Text

Duke Authors

Cited Authors

  • Lauriello, J; McEvoy, JP; Rodriguez, S; Bossie, CA; Lasser, RA

Published Date

  • January 1, 2005

Published In

Volume / Issue

  • 72 / 2-3

Start / End Page

  • 249 - 258

PubMed ID

  • 15560969

International Standard Serial Number (ISSN)

  • 0920-9964

Digital Object Identifier (DOI)

  • 10.1016/j.schres.2004.05.006


  • eng

Conference Location

  • Netherlands